COPD
Underwhelming results for GSK’s Relovair
January 10, 2012Research and Development, Sales and Marketing Advair, COPD, GSK, Relovair, Seretide, asthma
GlaxoSmithKline says it is on track to file its respiratory drug Relovair in Europe and the US despite mixed results …
NICE rejects Merck’s COPD drug Daxas
December 9, 2011Sales and Marketing COPD, Daxas, Merck, Nycomed
NICE has not recommended Merck’s COPD drug Daxas and is asking for a new clinical trial to test its effectiveness. …
Munro & Forster win PRCA Health and Wellbeing Award
November 28, 2011Medical Communications COPD, ERS, Munro & Forster, PRCA
Healthcare comms agency Munro & Forster has won an industry award for its innovative World Spirometry Day Campaign for the …
FDA delays decision on Novartis’ COPD drug
March 23, 2011Sales and Marketing COPD, Novartis, Onbrez Breezhaler, QAB149, bronchodilator, chronic obstructive pulmonary disease, indacterol
The FDA has delayed its licence decision on Novartis’ once-daily COPD treatment QAB149 by three months. The review process will …
Novartis’ COPD drug recommended for FDA approval
March 10, 2011Sales and Marketing Arcapta Neohaler, COPD, Novartis, Onbrez Breezhaler, QAB143, chronic obstructive pulmonary disease, indacterol
Novartis has won the backing of an FDA advisory committee for its chronic obstructive pulmonary disease (COPD) treatment QAB149. The …
Forest’s COPD drug approved in US
March 3, 2011Sales and Marketing COPD, Daliresp, Daxas, Forest, Forest Laboratories, chronic obstructive pulmonary disease, roflumilast
Daliresp (roflumilast) has been approved by the FDA to treat severe chronic obstructive pulmonary disease. Forest Laboratories’ once-daily pill is …
Digital Pharma: Pfizer and Boehringer’s online COPD awareness
November 12, 2010Medical Communications Boehringer Ingelheim, COPD, Digital Pharma blog, Managing COPD, NICE, Pfizer, Spiriva, chronic obstructive pulmonary disease
Pfizer and Boehringer Ingelheim have launched an online campaign to publicise the latest NICE guidelines on COPD to healthcare professionals …
Pfizer and Boehringer pilot COPD campaign
November 9, 2010Medical Communications Boehringer Ingelheim, COPD, Pfizer, Salford, chronic bronchitis, chronic obstructive pulmonary disease, emphysema
Pfizer and Boehringer Ingelheim have mobilised a soap opera star, painted rugby players and a special ‘breathing bus’ for a …
New COPD and asthma treatments jostle for market space
October 6, 2010Research and Development, Sales and Marketing COPD, Daxas, Onbrez Breezhaler, Revolair, asthma
Competition in the field of COPD and asthma is hotting up, with new data for several key treatments recently unveiled. …
Extra phase II studies boost GSK’s Relovair
September 23, 2010COPD, GlaxoSmithKline, Relovair, asthma
GlaxoSmithKline has conducted additional phase II trials on its asthma/COPD drug Relovair to answer a number of safety and efficacy …
Novartis hails longer-lasting COPD drug
September 20, 2010Research and Development, Sales and Marketing COPD, Novartis, Onbrez Breezhaler
A phase III treatment for COPD has demonstrated superior results over GSK’s established Serevent (salmeterol). Data from Novartis’ INSIST study …
Novartis’ COPD contender cleared in EU
December 4, 2009Sales and Marketing COPD, Novartis, resp
Novartis has been given a green light in the European Union to sell its Onbrez respiratory drug, allowing the firm …
GSK begins phase III COPD trials
October 28, 2009Research and Development, Sales and Marketing COPD, GSK, GlaxoSmithKline, Seretide, Theravance, resp, respiratory
GlaxoSmithKline and San Francisco biopharma firm Theravance have begun a phase III trial to develop a new treatment for chronic …
GP targets drive up COPD prescribing
May 27, 2009Sales and Marketing COPD, NHS, qof
Respiratory drugs saw the biggest growth in GP prescribing in England in 2008, thanks to new COPD targets.The rapid growth …
Phase III drug superior to Spiriva, says Novartis
May 21, 2009Research and Development, Sales and Marketing COPD, Novarits
Novartis says its COPD treatment has shown significant benefits over two established rivals, and could form the cornerstone of a …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
